Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo

• Published in: European journal of pharmacology 1996-09, Vol.312 (2), p.227-233
• Main Authors: TANIGUCHI, H, YAZAKI, N, YOMOTA, E, SHIKANO, T, ENDO, T, NAGASAKI, M
• Format: Article
• Language: English
• Subjects: Animals; Benzodiazepinones - pharmacology; Biological and medical sciences; Ceruletide - toxicity; Devazepide; Digestive system; Dogs; Female; Gastric Emptying; Indoles - pharmacology; Male; Medical sciences; Pancreas - drug effects; Pancreas - metabolism; Pancreatitis - chemically induced; Pharmacology. Drug treatments; Pregnancy; Proglumide - analogs & derivatives; Proglumide - pharmacology; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin A; Receptors, Cholecystokinin - antagonists & inhibitors; Sincalide - pharmacology
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/0014-2999(96)00473-6

The pharmacological profile of a new CCKA receptor antagonist, T-0632 [sodium (S)-1-(2-fluorophenyl)-2,3-dihydro-3-[(3-isoquinolinylcarbonyl) amino]-6-methoxy-2-oxo-1H-indole-3-propanoate], was examined in in vivo studies and compared with those of L-364, 718 [3S(-)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1, 4-benzodiazepine-3-yl)-1 H-indole-2-carboxamide] and loxiglumide [D.L-4-(3,4-dichlorobenzoylamino)-5-(N-3-methoxypropyl-pentylam ino)-5- oxopentanoic acid]. In rats, intravenously administered T-0632, L-364,718 and loxiglumide dose dependently inhibited cholecystokinin octapeptide (CCK-8)-stimulated pancreatic exocrine secretion with estimated ED50 values of 0.025, 0.016 and 1.8 mg/kg, respectively. The ED50 values for intraduodenal administration of these compounds were 0.040, 0.26 and 3.0 mg/kg, respectively. In mice, orally administered T-0632 prevented caerulein-induced pancreatitis, CCK-8-induced inhibition of gastric emptying and CCK-8-induced gallbladder emptying in dose-dependent manners with ED50 values of 0.028, 0.04, and 0.12 mg/kg, respectively. The effect of T-0632 for caerulein-induced pancreatitis was 4-fold more potent than that for gallbladder emptying. In contrast, the effects of L-364,718 and loxiglumide for caerulein-induced pancreatitis were 2-4-fold weaker than those for gallbladder emptying. In dogs, T-0632 and loxiglumide maximally inhibited CCK-8-stimulated pancreatic amylase secretion at doses of 0.01 and 10 mg/kg, respectively. At these doses, the effect of T-0632 on CCK-8-induced increase in the gallbladder intraluminal pressure was weaker than that of loxiglumide. These results suggest that T-0632 has a potent antagonistic action on CCKA receptors in several animal species and the effects of T-0632 are more selective for the pancreas over the gallbladder compared with L-364,718 and loxiglumide.